Literature DB >> 7437268

Double-blind cross-over comparison of hydralazine and prazosin in hypertensive subjects on a beta-adrenoceptor blocking agent (atenolol).

J V Jones, J M Steiner.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7437268      PMCID: PMC1430156          DOI: 10.1111/j.1365-2125.1980.tb01802.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  5 in total

1.  Studies with prazosin--a new effective hypotensive agent. III. An acute double-blind cross-over study comparing the effects of single doses of prazosin and hydrallazine in combination with propranolol and a diuretic.

Authors:  A S Hua; J B Myers; P Kincaid-Smith
Journal:  Med J Aust       Date:  1978-01-14       Impact factor: 7.738

2.  Treatment of essential hypertension with a new vasodilator in combination with beta-adrenergic blockade.

Authors:  E Gilmore; J Weil; C Chidsey
Journal:  N Engl J Med       Date:  1970-03-05       Impact factor: 91.245

3.  Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade.

Authors:  R Zacest; E Gilmore; J Koch-Weser
Journal:  N Engl J Med       Date:  1972-03-23       Impact factor: 91.245

4.  Relation of hydralazine plasma concentration to dosage and hypotensive action.

Authors:  R Zacest; J Koch-Weser
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

5.  Hydrallazine or phentolamine as adjuncts to beta-adrenoceptor blockade/thiazide therapy in hypertension.

Authors:  J F Winchester; D M Ward; J H McKillop; A C Kennedy
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

  5 in total
  1 in total

Review 1.  Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.

Authors:  W F Stanaszek; D Kellerman; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.